Tight blood pressure management: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg.
Routine blood pressure management: ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. Intraoperative blood pressure will be managed per clinical routine.
Study summary
An international randomized trial to test the primary hypothesis that perioperative tight blood pressure management reduces a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.
The treatments will be: 1) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg (tight pressure management); or, 2) routine intraoperative blood pressure management (routine pressure management).
Eligibility
Sex
ALL
Min age
45 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. At least 45 years old;
2. Scheduled for major noncardiac surgery expected to last at least 2 hours;
3. Having general anesthesia, neuraxial anesthesia, or the combination;
4. Expected to require at least overnight hospitalization (planned ICU admission is acceptable);
5. Are designated ASA physical status 2-4 (ranging from mild systemic disease through severe systemic disease that is a constant threat to life);
6. Expected to have direct intraoperative blood pressure monitoring with an arterial catheter;
7. Cared for by clinicians willing to follow the GUARDIAN protocol;
8. Subject to at least one of the following risk factors:
1. Age \>65 years;
2. History of peripheral arterial disease;
3. History of coronary artery disease;
4. History of stroke or transient ischemic attack;
5. Serum creatinine \>175 μmol/L (\>2.0 mg/dl) within 6 months;
6. Diabetes requiring medication;
7. Current smoking or 15 pack-year history of smoking tobacco;
8. Scheduled for major vascular surgery;
9. Body mass index ≥35 kg/m2;
10. Preoperative high-sensitivity troponin T \>14 ng/L or troponin I equivalent, defined as ≥15 ng/L (Abbott assay), 19 ng/L (Siemens assay, \[Borges, unpublished\]), or 25% of the 99% percentile for other assays - all within 6 months;
11. B-type natriuretic protein (BNP) \>80 ng/L or N-terminal B-type natriuretic protein (NTProBNP) \>200 ng/L within six months.
Exclusion Criteria:
1. Are scheduled for carotid artery surgery;
2. Are scheduled for intracranial surgery;
3. Are scheduled for partial or complete nephrectomy;
4. Are scheduled for pheochromocytoma surgery;
5. Are scheduled for liver or kidney transplantation;
6. Require preoperative intravenous vasoactive medications;
7. Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;
8. Require beach-chair positioning;
9. Have a documented history of dementia;
10. Have language, vision, or hearing impairments that may compromise cognitive assessments;
11. Have contraindications to norepinephrine or phenylephrine per clinician judgement;
12. Have previously participated in the GUARDIAN trial.
Primary outcome measure(s)
Number of Participants with a Composite of Major Perfusion-Related Complications — During the initial 30 days after major non-cardiac surgery The primary outcome is a composite of major perfusion-related complications (myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death) in the 30 days after major non-cardiac surgery.
Trial sites (20)
Facility
City
Region
Status
University of Nebraska Medical Center
Omaha
Nebraska
Completed
Wake Forest University
Wake Forest
North Carolina
Completed
MetroHealth Medical Center
Cleveland
Ohio
Recruiting
Cleveland Clinic Fairview Hospital
Cleveland
Ohio
Completed
Cleveland Clinic Main Campus
Cleveland
Ohio
Completed
The University of Texas Health Science Center at Houston
Houston
Texas
Recruiting
Beijing Shijitan Hospital, Capital Medical University
Beijing
China
Recruiting
Peking Union Medical College Hospital
Beijing
China
Recruiting
Peking University First Hospital
Beijing
China
Recruiting
West China University Hospital
Chengdu
China
Recruiting
Prince of Wales Hospital, Chinese University of Hong Kong, Shatin
Hong Kong
China
Recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai
China
Recruiting
Shanghai Chest Hospital
Shanghai
China
Recruiting
Shanghai Ninth People's Hospital
Shanghai
China
Recruiting
The Affiliated Lianyungang Hospital of Xuzhou Medical University
Xuzhou
China
Recruiting
University of Thessaly
Larissa
Greece
Completed
IRCCS Regina Elena National Cancer Institute
Rome
Italy
Recruiting
National Defense Medical College
Tokyo
Japan
Recruiting
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Bakırköy
Turkey (Türkiye)
Recruiting
Konya City Hospital
Konya
Turkey (Türkiye)
Recruiting
More The University of Texas Health Science Center, Houston trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.